[Sclerostin: a new biomarker of interest in nephrology].

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Annales de Biologie Clinique

• Publication date

  2015-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1684/abc.2015.1049PMID 26069067
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study.

  2015cited by this paper
• Effects of age on bone mRNA levels of sclerostin and other genes relevant to bone metabolism in humans.

  2014cited by this paper
• Serum sclerostin is an independent predictor of mortality in hemodialysis patients

  2014cited by this paper
• Serum sclerostin levels vary with season.

  2014cited by this paper
• Sclerostin in Institutionalized Elderly Women: Associations with Quantitative Bone Ultrasound, Bone Turnover, Fractures, and Mortality

  2014cited by this paper
• Uremic toxicity and sclerostin in chronic kidney disease patients.

  2014cited by this paper
• Clinical and Biological Determinants of Sclerostin Plasma Concentration in Hemodialysis Patients

  2014cited by this paper
• Renal elimination of sclerostin increases with declining kidney function.

  2014cited by this paper
• Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study

  2013cited by this paper
• Association of circulating sclerostin with bone mineral mass, microstructure, and turnover biochemical markers in healthy elderly men and women.

  2013cited by this paper
• The relation between renal function and serum sclerostin in adult patients with CKD.

  2013cited by this paper
• Fibroblast growth factor 23, Klotho, and disordered mineral metabolism in chronic kidney disease: unraveling the intricate tapestry of events and implications for therapy.

  2013cited by this paper
• Atherosclerotic Disease in Type 2 Diabetes Is Associated With an Increase in Sclerostin Levels

  2013cited by this paper
• Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study

  2013cited by this paper
• Novel insights into osteogenesis and matrix remodelling associated with calcific uraemic arteriolopathy.

  2013cited by this paper
• Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis?

  2013cited by this paper
• Sclerostin: Another vascular calcification inhibitor?

  2013cited by this paper
• Sclerostin is expressed in articular cartilage but loss or inhibition does not affect cartilage remodeling during aging or following mechanical injury.

  2013cited by this paper
• Sclerostin Regulates Release of Bone Mineral by Osteocytes by Induction of Carbonic Anhydrase 2

  2013cited by this paper
• Sclerostin as a potential novel biomarker for aortic valve calcification: an in-vivo and ex-vivo study.

  2013cited by this paper
• Correlates of bone microarchitectural parameters and serum sclerostin levels in men: The STRAMBO study

  2013cited by this paper
• Increased serum sclerostin and decreased serum IGF-1 are associated with vertebral fractures among postmenopausal women with type-2 diabetes.

  2013cited by this paper
• Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients.

  2012cited by this paper
• Circulating Sclerostin and Dickkopf-1 (DKK1) in Predialysis Chronic Kidney Disease (CKD): Relationship with Bone Density and Arterial Stiffness

  2012cited by this paper
• High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: The center of excellence for osteoporosis research study

  2012cited by this paper
• Serum sclerostin and risk of hip fracture in older Caucasian women.

  2012cited by this paper
• Serum sclerostin levels were positively correlated with fat mass and bone mineral density in Central South Chinese postmenopausal women

  2012cited by this paper
• Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases.

  2012cited by this paper
• Decreased serum sclerostin levels in patients with primary hyperparathyroidism: a cross-sectional and a longitudinal study

  2012cited by this paper
• Update on Wnt signaling in bone cell biology and bone disease.

  2012cited by this paper
• Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women—the six-month effect of risedronate and teriparatide

  2011cited by this paper
• Single‐dose, placebo‐controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

  2011cited by this paper
• Sclerostin Stimulates Osteocyte Support of Osteoclast Activity by a RANKL-Dependent Pathway

  2011cited by this paper
• Sclerostin: just one more player in renal bone disease?

  2011cited by this paper
• Determinants of serum sclerostin in healthy pre‐ and postmenopausal women

  2011cited by this paper
• Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women

  2011cited by this paper
• Sclerostin and Dickkopf-1 in renal osteodystrophy.

  2011cited by this paper
• Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones

  2011cited by this paper
• Delayed bone regeneration and low bone mass in a rat model of insulin-resistant type 2 diabetes mellitus is due to impaired osteoblast function.

  2011cited by this paper
• Relation of Age, Gender, and Bone Mass to Circulating Sclerostin Levels in Women and Men

  2010cited by this paper
• Distinct Modes of Inhibition by Sclerostin on Bone Morphogenetic Protein and Wnt Signaling Pathways*

  2010cited by this paper
• A Rational Guide to Reducing Fracture Risk in Dialysis Patients

  2010cited by this paper
• Sclerostin antibody treatment enhances metaphyseal bone healing in rats

  2010cited by this paper
• Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss.

  2010cited by this paper
• Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls.

  2010cited by this paper
• Does osteocytic SOST suppression mediate PTH bone anabolism?

  2010cited by this paper
• Sclerostin: Current Knowledge and Future Perspectives

  2010cited by this paper
• Parathyroid Hormone (PTH)–Induced Bone Gain Is Blunted in SOST Overexpressing and Deficient Mice

  2009cited by this paper
• Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis

  2009cited by this paper
• One Year of Transgenic Overexpression of Osteoprotegerin in Rats Suppressed Bone Resorption and Increased Vertebral Bone Volume, Density, and Strength

  2009cited by this paper
• Sclerostin Mediates Bone Response to Mechanical Unloading Through Antagonizing Wnt/β‐Catenin Signaling

  2009cited by this paper
• Targeted Deletion of the Sclerostin Gene in Mice Results in Increased Bone Formation and Bone Strength

  2008cited by this paper
• Mechanical Stimulation of Bone in Vivo Reduces Osteocyte Expression of Sost/Sclerostin*

  2008cited by this paper
• Adynamic bone in patients with chronic kidney disease.

  2008cited by this paper
• Vascular calcification and osteoporosis—from clinical observation towards molecular understanding

  2007cited by this paper
• Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis.

  2005cited by this paper
• Bone mineral density in sclerosteosis; affected individuals and gene carriers.

  2005cited by this paper
• Sclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling*

  2005cited by this paper
• Sclerostin Is an Osteocyte-expressed Negative Regulator of Bone Formation, But Not a Classical BMP Antagonist

  2004cited by this paper
• The natural history of sclerosteosis

  2003cited by this paper
• Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein.

  2001cited by this paper
• Serum levels of 1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, and 25-hydroxyvitamin D in nondialyzed patients with chronic renal failure.

  1999cited by this paper
• Direct effect of phosphorus on PTH secretion from whole rat parathyroid glands in vitro

  1996cited by this paper
• The role of the parathyroid glands in the uremic syndrome.

  1995cited by this paper
• Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis.

  1993cited by this paper
• The clinical features of sclerosteosis. A review of the manifestations in twenty-five affected individuals.

  1976cited by this paper
• Hyperostosis corticalis generalisata. Eight new cases.

  1971cited by this paper
• Hyperostosis corticalis generalisata. Report of seven cases.

  1962cited by this paper
• An uncommon familial systemic disease of the skeleton: hyperostosis corticalis generalisata familiaris.

  1955cited by this paper

• Bone-formation-related markers in osteonecrosis of the jaws and their correlation with radiographic findings

  2025cites this paper